Ablative Solutions completes $9.

Ablative Solutions completes $9.5M Series B Preferred Stock financing Ablative Solutions, Inc viagra generic ., a privately-held clinical stage company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, today that it has completed a Series B Preferred Stock funding announced, totaling approximately $9.5 million , to fund its unique technology system for renal denervation. The round was led by BioStar Ventures and Michigan Accelerator Fund, and included participation by the founders and multiple angel investors. ‘THE BUSINESS has made tremendous improvement in the two years since its inception with a distinctive approach to renal denervation, and has done so with great capital effectiveness,’ affirmed Dale Grogan of Michigan Accelerator Fund, who was simply elected to the Company's Board of Directors upon closing of the funding.

Copyright blindserver.com 2018